Lantern Pharma and TTC Oncology Establish AI Collaboration to Expand the Clinical Development of Drug Candidate TTC-352
~ Collaborative efforts are aimed at using Lantern’s AI platform to accelerate and sharpen the drug development of TTC-352. ~ The collaboration will utilize Lantern’s AI-based capabilities and RADR® platform to uncover efficacy-associated biological signatures and biomarkers to advance the clinical development and strategic positioning of TTC Oncology’s leading drug candidate, TTC-352. ~ Phase 2 ready candidate, TTC-352, is a novel, first- and best-in-class selective human estrogen receptor (ER) partial agonist (ShERPA) for the treatment of patients with metastatic ER+ breast cancer. ~ Lantern is receiving exclusive rights to license TTC-352 during an exclusive option period, which includes rights to intellectual property generated during the collaboration.
To create an account please click on this link.
If you already have an account, please log in here.